Alnylam Pharmaceuticals
ALNY
#578
Rank
$34.74 B
Marketcap
$268.46
Share price
-0.94%
Change (1 day)
75.09%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Alnylam Pharmaceuticals (ALNY) - Total debt

Total debt on the balance sheet as of December 2024 : $1.29 Billion USD

According to Alnylam Pharmaceuticals 's latest financial reports the company's total debt is $1.29 Billion USD. A companyโ€™s total debt is the sum of all current and non-current debts.

Alnylam Pharmaceuticals - Total debt on balance sheet (from 2003 to 2024)

Total debt by year

Year Total debt Change
2024-12-31$1.29 B-0.72%
2023-12-31$1.30 B-1.13%
2022-12-31$1.32 B32.34%
2021-12-31$0.99 B91.41%
2020-12-31$0.52 B71.54%
2019-12-31$0.30 B912.74%
2018-12-31$30 M0%
2017-12-31$30 M-80%
2016-12-31$0.15 B
2007-12-31$6.75 M-26.03%
2006-12-31$9.13 M23.54%
2005-12-31$7.39 M2.69%
2004-12-31$7.2 M287.36%
2003-12-31$1.85 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
$0.52 B-59.47%๐Ÿ‡บ๐Ÿ‡ธ USA
$2.70 B 108.66%๐Ÿ‡บ๐Ÿ‡ธ USA
$1.34 B 3.63%๐Ÿ‡บ๐Ÿ‡ธ USA
$0.50 B-61.08%๐Ÿ‡บ๐Ÿ‡ธ USA
$0.27 M-99.98%๐Ÿ‡บ๐Ÿ‡ธ USA
$31.25 B 2,311.79%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
$18.63 B 1,337.70%๐Ÿ‡ซ๐Ÿ‡ท France
$18.07 B 1,294.93%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel